Antiplatelet therapy combination

This page covers all Antiplatelet therapy combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Platelet aggregation pathways (cyclooxygenase and P2Y12 receptor), P2Y12 receptor and cyclooxygenase (COX).

Targets

Platelet aggregation pathways (cyclooxygenase and P2Y12 receptor) · P2Y12 receptor and cyclooxygenase (COX)

Marketed (1)

• extended postimplantation dual antiplatelet therapy · National Institute of Cardiology, Warsaw, Poland · Cardiovascular
  Extended dual antiplatelet therapy (typically aspirin plus a P2Y12 inhibitor) prevents stent thrombosis and reduces cardiovascular events by inhibiting platelet aggregation for a prolonged period after coronary stent implantation.

Phase 3 pipeline (1)

• DAPT strategy · Assistance Publique - Hôpitaux de Paris · Cardiovascular
  DAPT (Dual Antiplatelet Therapy) strategy involves the concurrent use of two antiplatelet agents to prevent thrombotic events in cardiovascular disease.